drugset / Trial / NCT00955409
Long Term Extension Study Evaluating Safety, Tolerability and Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease
Phase 2
Completed
160 enrolled
Pfizer
JANSSEN Alzheimer Immunotherapy Research & Development, LLC · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to assess the long term safety, tolerability, and immunogenicity of ACC-001, an investigational active immunization product+, in subjects with mild to moderate Alzheimer's disease.
Timeline
- Start
- 2009-11-05
- Primary completion
- 2013-12-17
- Completion
- 2013-12-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Vanutide Cridificar | Vaccine | 3 ug | Intramuscular |
| Subject | Vanutide Cridificar | Vaccine | 10 ug | Intramuscular |
| Subject | Vanutide Cridificar | Vaccine | 30 ug | Intramuscular |
| Background | QS-21 | Other / unclassified | 50 ug | Intramuscular |